Pharmacological modulators of DNA-interactive antitumor drugs

https://doi.org/10.1016/0165-6147(89)90010-2Get rights and content

Abstract

The poor therapeutic index and limited efficacy of current cancer chemother-apeutic agents represent an important pharmacological problem. Athough there has been a significant increase in our understanding of the mechanisms by which anticancer drugs kill mammalian cells, identification of new, effective anticancer agents during the last decade has been exceeding slow. Thus, attention has focused on understanding the causes of drug resistance and on either sensitizing tumor cells to existing anticancer agents using what could be called ‘chemoenhancers’, or protecting non-malignant tissues against serious untoward effects using ‘chemoprotectors’. John Lazo and Robert Bahnson review recent strategies attempting to modulate the activity of antineovlastic drugs.

References (33)

  • L.H. Hurley et al.

    Trends Pharmacol Sci.

    (1988)
  • J.R. Riordan et al.

    Pharmacol. Ther.

    (1985)
  • M.M. Gottesman et al.

    Trends Pharmacol Sci.

    (1988)
  • S. Ahmad et al.

    J. Biol. Chem.

    (1987)
  • W.T. Bellamy et al.

    Biochem. Pharmacol.

    (1989)
  • S. Somfai-Relle et al.

    Biochem. Pharmacol.

    (1984)
  • R.F. Ozols

    Biochem. Pharmacol.

    (1987)
  • S. Somfai-Relle et al.

    Cancer Treat. Rev.

    (1984)
  • A. Bakka et al.

    Toxicol. Appl. Pharmacol.

    (1981)
  • A. Zelazowski et al.

    Arch. Biochem. Biophys.

    (1984)
  • A. Kraker et al.

    Biochem. Biophys. Res. Commun.

    (1985)
  • B.A. Teicher

    Cancer Res.

    (1987)
  • W.S. Dalton

    J. Clin. Oncol.

    (1989)
  • A. Ramu
  • L.M. Slater et al.

    Br. J. Cancer

    (1986)
  • R.F. Ozols

    J. Clin. Oncol.

    (1987)
  • Cited by (16)

    • Gene expression profiles in the liver and kidney of metallothionein-null mice

      2005, Biochemical and Biophysical Research Communications
    View all citing articles on Scopus
    View full text